Anticoagulants

Front 1

At low doses this an antiplatelet drug inhibits synthesis of thromboxane A2 by irreversible acetylation of the enzyme cyclooxygenase (COX-1)

Back 1

Aspirin; 325mg QD.

Front 2

At higher dose this drug does not improve in efficacy and leads to inhibition in prostacyclin production.

Back 2

ASA

Front 3

This drug is the antiplatelet drug of choice and unless contraidicated 2/2 allergy or intolerance is the first to be prescribed.

Back 3

ASA

Front 4

This drug is a vasodilator that inhibits platelte function by inhibition of PDE which increases cAMP reducing platelet aggregation.

Back 4

Dipyridamole (persantine & aggrenox).

Front 5

Dipyridamole also has two other MOA they are...

Back 5

1. inhibition of thromboxane synthase, leads to reduced TXA2 levels.
2. Inhibition of adenosine uptake

Front 6

Primary use for dipyridamole is what?

Back 6

combo with ASA to prevent CV ischemia.

Front 7

These two anitplatelet drugs by irreversibly inhibiting ADP receptor resulting in higher levels of cAMP and decrease platelet aggregation. Both require conversion to an active metabolite.

Back 7

Ticlopidine (Ticlid)
Clopidogrel (Plavix)

Front 8

This antiplatelet drug is a fab fragment of humanized monoclonal antibody directed against the GFP11b receptor.

Back 8

Abciximab (reopro)

Front 9

This antiplatelet drug is a cyclic peptide inhibitor of the fibrinogen binding site on the GFPIIb receptor

Back 9

Eptifibatide

Front 10

This anticoagulant works by inhibition of clotting factors IXa, Xa and thrombin by enhancing antithrombin III activity.

Back 10

HMW heparin. Does NOT cross the placent and is safe in preganacy.

Front 11

This anticoagulant works by inhibiting Xa by binding to antithrombin.

Back 11

LMW heparin.

Front 12

This anticoagulant inhibits vitamin K req for synthesis of prothrombin, VII, IX, and X.

Back 12

Warfarin

Front 13

This anticoagulant is a direct thrombin inhibitor and is a pro-drug rapidly (1hr) converted to active form.

Back 13

Dabigatran Etexilate (Pradaxa)

Front 14

This is a thrombolytic produced from streptococcus. It acts T/O the circulation and catalyzes the conversion of inactive plasminogen to plasmin.

Back 14

Streptokinase.

Front 15

This group of thrombolytics activates plasminogen that is bound to fibrin, which in theory confines fibrinolysis to the formed thrombus and AVOIDS systemic circulation. Acts on plasminogen only at site of clot.

Back 15

Tissue plasminogen activator (tPA, altepase, activase).

Front 16

This thrombolytic is a fragment of tPA gene cloned. Like tPA acts on plasminogen at site of clot. It is less firbrin specific then t-PA

Back 16

Reteplase (retavase)

Front 17

This thrombolytic is a fragment of human tPA gene cloned; genetically expressed. More clot specific then tPA and has some resistence to plasminogen inhibitors

Back 17

Tenectelplase (TNKase)